Results 131 to 140 of about 8,055 (251)

Effects of GLP‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review

The FEBS Journal, EarlyView.
This systematic review evaluated 17 studies (12 preclinical and five clinical) on GLP‐1 receptor agonists in type 2 diabetes, demonstrating effects on the gut microbiota and metabolic improvement. The studies showed an increase in Bacteroidetes, Lactobacillus, and Akkermansia, and a reduction in Firmicutes.
Ranicleide Santos Dantas, Lucas Vinícius Souza Santos, André Gustavo Carvalho de Oliveira, Marina dos Santos Barreto, Deise Maria Rego Rodrigues Silva, Pedro Henrique Macedo Moura, Eloia Emanuelly Dias Silva, Ronaldy Santana Santos, Lucas Alves da Mota Santana, Rajiv Gandhi Gopalsamy, Adriana Gibara Guimarães, Lysandro Pinto Borges   +11 more
wiley   +1 more source

Comparative Effectiveness of GLP‐1RAs, SGLT2is and DPP4is for Cardiovascular Outcomes in Type 2 Diabetes: An Empirically Calibrated Target Trial Emulation Study

Diabetes, Obesity and Metabolism, EarlyView.
Bingyu Zhang, Ting Zhou, Huilin Tang, Yiwen Lu, Dazheng Zhang, Jiajie Chen, Tianchu Lyu, Kai Zheng, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Use of glucagon‐like peptide‐1 receptor agonists is associated with inadequate bowel preparation for colonoscopy in patients with diabetes

Journal of Diabetes Investigation, EarlyView.
In Japanese patients with diabetes undergoing colonoscopy, GLP‐1RA use was associated with a higher rate of inadequate bowel preparation after propensity score matching. Weekly formulations showed a higher rate than daily formulations, while additional adjusted analyses were directionally consistent but not statistically significant.
Osamu Ogawa
wiley   +1 more source

Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Type 1 diabetes is defined by immune‐mediated beta‐cell failure and dependence on exogenous insulin. That definition is correct, but it may not fully describe many people seen in current clinical practice. Overweight and obesity are now common in type 1 diabetes, leading to variable combinations of high insulin requirement, hypertension ...
Zachary Bloomgarden
wiley   +1 more source

Discontinuation of Glucagon‐Like Peptide‐1 Receptor Agonists After Bowel Obstruction or Ileus: A Nationwide, Real‐World, Database Study

Journal of Evidence-Based Medicine, EarlyView.
ABSTRACT Objective Although concerns have been raised that glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) may increase the risk of bowel obstruction or ileus, evidence remains inconclusive. In this context of uncertainty, we examined the frequency and determinants of GLP‐1RA discontinuation after hospitalization for bowel obstruction/ileus ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

Tirzepatide – new treatment option for patient with type 2 diabetes [PDF]

Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica MoldovaIntroduction. Type II diabetes is a global problem of the 21st century.
Mufeed, Majeed
core  

Global Burden of Key Components of Cardiovascular–Kidney–Metabolic Syndrome Among Women of Reproductive Age, 1990–2021

Journal of Evidence-Based Medicine, EarlyView.
ABSTRACT Objective Cardiovascular–kidney–metabolic (CKM) syndrome links metabolic, kidney, and cardiovascular disorders, but its burden among women of reproductive age (WRA) remains poorly understood. We quantified the global burden and trends of key CKM‐related conditions and high body mass index (BMI)‐attributable burden among WRA.
Cuiping Jiang, Jieyuzhen Qiu, Chuanli Wei, Enhui Zhou, Huaming Zhu, Weijun Huang, Tianjiao Zhou, Ji Hu   +7 more
wiley   +1 more source

Comparative Efficacy of Semaglutide and Tirzepatide in Chinese Adults with Obesity without Diabetes: A Real-World Observational Study. [PDF]

Diabetes Metab Syndr Obes
Yao Z, Ahmad A, Gong F, Zhang N, Zeng M, Ge Q.   +5 more
europepmc   +1 more source

Trends in GLP‐1‐Based Therapy Use Before and After Pregnancy

Diabetes, Obesity and Metabolism, EarlyView.
Nansi S. Boghossian, Lauren McAbee, Antonio F. Saad, Maged M. Costantine, Marwan Ma'ayeh, Joseph A. Ewing   +5 more
wiley   +1 more source

Beyond Weight Loss: Tirzepatide as a Metabolic Disease-Modifying Strategy for Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review. [PDF]

Health Sci Rep
Ahmed Z, Mustafa N, Sarkar T, Yasmin H.
europepmc   +1 more source